(±)-Nantenine analogs as antagonists at human 5-HT2A receptors: C1 and flexible congeners

Chaudhary, Sandeep; Pecic, Stevan; LeGendre, Onica; Navarro, Hernán A.; Harding, Wayne W.

doi:10.1016/j.bmcl.2009.03.048

Cited by 23 publications

(38 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22,25 Thus, it was of interest to determine if a similar alkylation strategy would be beneficial for 5-HT 1A affinity in the case of N-methyllaurotetanine at the C-9 position.…”

Section: ■ Results and Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors

Madapa

Harding

2015

J. Nat. Prod.

Self Cite

View full text Add to dashboard Cite

N-Methyllaurotetanine (1) has been reported to display good affinity for the 5-HT1A receptor, but no structure-affinity studies have been performed to date. The commercially available alkaloid boldine (2) was used as the starting material for synthesis of various C-9 alkoxy analogues of N-methyllaurotetanine in order to gauge the effect of C-9 alkylation on affinity and selectivity at 5-HT1A, 5-HT2A, and 5-HT7 receptors. Mitsunobu reactions were implemented in the alkylation steps leading to the analogues. Modest improvement in 5-HT1A affinity was observed upon alkylation for most analogues. Thus, the C-9 hydroxy group of 1 is not critical for affinity to the 5-HT1A receptor. Some analogues displayed high affinity for the 5-HT7 receptor, comparable to N-methyllaurotetanine, with moderate selectivity vs 5-HT1A and 5-HT2A receptors.

show abstract

“…22,25 Thus, it was of interest to determine if a similar alkylation strategy would be beneficial for 5-HT 1A affinity in the case of N-methyllaurotetanine at the C-9 position.…”

Section: ■ Results and Discussionmentioning

confidence: 99%

“…22,23,25,30 The 1,2,9,10-tetraoxygenated pattern seems to endow aporphines with a bias for affinity to 5-HT receptors. However, an extensive evaluation of the impact of structural manipulations on the affinity of this scaffold across various 5-HT receptors is in need of attention.…”

mentioning

confidence: 95%

Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors

Madapa

Harding

2015

J. Nat. Prod.

Self Cite

View full text Add to dashboard Cite

show abstract

“…We have recently reported further investigations at the C1 position and have identified new 5-HT 2A antagonists up to 12 times more potent than nantenine. 24, 25 …”

Section: Introductionmentioning

confidence: 99%

New aporphinoid 5-HT2A and α1A antagonists via structural manipulations of nantenine

Chaudhary¹,

Ponnala²,

LeGendre³

et al. 2011

Bioorganic & Medicinal Chemistry

Self Cite

View full text Add to dashboard Cite

A series of C1, C2, C3 and N6 analogs of nantenine (2) was synthesized and evaluated in 5-HT2A and α1A receptor functional assays. Alkyl substitution of the C1 and N6 methyl groups of nantenine provided selective 5-HT2A and α1A antagonists respectively. The C2 alkyloxy analogs studied were generally selective for α1A vs 5-HT2A. The C3 bromo analog 15 is one of the most potent aporphinoid 5-HT2A antagonists known presently.

show abstract

“…[15][16][17] As part of those efforts, we decided to investigate the importance of molecular rigidity of the aporphine template on 5-HT 2A antagonism. In that regard, we decided to explore whether the replacement of the N-methyl group of nantenine with an N-phenylalkyl moiety and concomitant increase in flexibility would affect 5-HT 2A antagonist activity.…”

mentioning

confidence: 99%

Identification of tris-(phenylalkyl)amines as new selective h5-HT_2B receptor antagonists

2015

View full text Add to dashboard Cite

A series of tris-Ĳphenylalkyl)amines was synthesized and evaluated for affinity to human 5-HT 2 receptors. In general, the compounds displayed high affinity (4 of 11 analogs had K i values < 10 nM) and good selectivity for the 5-HT 2B receptor vs. other 5-HT 2 receptors. Functional assays revealed that the compounds are 5-HT 2B antagonists.The 5-HT 2B receptor is involved in regulation of the CNS, gastric and intestinal motility and cardiovascular function. 5-HT 2B antagonists have been explored as potential pharmacotherapies for migraine, 1 irritable bowel syndrome, 2-4 pulmonary hypertension 5 and heart failure. 6 5-HT 2B receptor agonists display antidepressant activity and 5-HT 2B receptor activation is required for antidepressant actions of selective serotonin reuptake inhibitors (SSRI's). 7 However, 5-HT 2B agonism is known to be associated with the development of valvular heart disease (VHD) and as such is regarded as an anti-target in most drug discovery programs. [8][9][10] Despite the promise of 5-HT 2B antagonists as useful therapeutics, there are no 5-HT 2B antagonists that are clinically approved for the clinical indications mentioned previously. This is partly because many known ligands are not truly 5-HT 2B selective Ĳ5-HT 2B ligands often also have affinity for the related 5-HT 2A and 5-HT 2C receptors) and even when selective there are issues related to ADME properties of the compounds that prohibit clinical translational studies. Fig. 1 shows some selective 5-HT 2B antagonists that are commercially available; these compounds are predominantly used as biological tools. 11-14 The identification of new 5-HT 2B preferring scaffolds is critical in the pursuit of novel chemical entities that may be developed as useful 5-HT 2B antagonist therapeutics. We describe herein the serendipitous discovery of a new series of ligands bearing a tris-Ĳphenylalkyl)amine scaffold with high affinity and selectivity for the 5-HT 2B receptor. The ease of synthesis of this scaffold makes it particularly attractive for further structure-activity work to optimize 5-HT 2B affinity, selectivity and antagonist activity in the quest for 5-HT 2B antagonist drugs.Our research team has been investigating aporphines based on the natural product nantenine (see inset, Scheme 1) as ligands for the 5-HT 2A receptor and this program has resulted in the identification of a number of new aporphinebased 5-HT 2A antagonists. [15][16][17] As part of those efforts, we decided to investigate the importance of molecular rigidity of the aporphine template on 5-HT 2A antagonism. In that regard, we decided to explore whether the replacement of the N-methyl group of nantenine with an N-phenylalkyl moiety and concomitant increase in flexibility would affect 5-HT 2A antagonist activity. We considered that this approach might allow the ligands multiple possibilities for interaction of the receptor with N-phenylalkyl groups which seem to be important pharmacophoric recognition elements in 5-HT 2A ligands, thus leading to increase in 5-HT 2A receptor ...

show abstract

(±)-Nantenine analogs as antagonists at human 5-HT2A receptors: C1 and flexible congeners

Cited by 23 publications

References 31 publications

Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors

Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors

New aporphinoid 5-HT2A and α1A antagonists via structural manipulations of nantenine

Identification of tris-(phenylalkyl)amines as new selective h5-HT_2B receptor antagonists

Contact Info

Product

Resources

About

(±)-Nantenine analogs as antagonists at human 5-HT2A receptors: C1 and flexible congeners

Cited by 23 publications

References 31 publications

Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors

Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors

New aporphinoid 5-HT2A and α1A antagonists via structural manipulations of nantenine

Identification of tris-(phenylalkyl)amines as new selective h5-HT2B receptor antagonists

Contact Info

Product

Resources

About

Identification of tris-(phenylalkyl)amines as new selective h5-HT_2B receptor antagonists